Guangzhou Kingmed has led a $31m series C round for genome sequencing company Yikon Genomics, which was spun out of Harvard University five years ago.

Bayer has led a $25m series B round for Medopad, which allows patients to capture healthcare data through smartphones and watches.

UCSD-founded Shape Therapeutics has collected series A cash from NEA and CureDuchenne Ventures to progress its RNA gene editing technology.

Building on the work of University of Sydney researchers, Kira Biotech has raised $13.6m from investors including IP Group to progress antibodies for autoimmune diseases.

Sino Biopharmaceutical has co-led the series D round together with Loyal Valley Capital, while K. Wah Group also contributed.

Merck Global Health Innovation Fund and Bristol-Myers Squibb have provided the final tranche for PathAI’s $75m series B round, adding to an earlier commitment from LabCorp.

Chinese Academy of Sciences' Cash Capital put up a share of the funds for oncological drug developer OnQuality Pharmaceuticals' first funding round.

Sensely has collected funding from a consortium led by insurance firm Aflac to haul its lifetime total to $26.5m.

Stanford-StartX Fund portfolio company Sensely collected funding from a consortium led by insurance firm Aflac to haul its lifetime total to $26.5m.

Genomics bioinformatics platform developer PierianDx has raised capital from investors including Inova Health Systems and RTI International to advance its business strategy.